ADIPOR1 and metabolic dysfunction-associated steatotic liver disease: Moreover, our data indicates that YCLLT-MS promoted the activation of the AdipoR1/AMPK/SIRT1 signaling pathway and may inhibit lipid deposition, inflammatory injury, and ameliorate mitochondrial dysfunction in the NAFLD cell model by regulating AdipoR1.